ClinicalTrials.govpublic full text
Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT
multiple myeloma, non-eligible for autologous stem cell transplantation (asct), prospective, observational study, observational
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 981212
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.